Control of Cell Cycle and Cell Proliferation

Control of Cell Cycle and Cell Proliferation, Volume 135 in the Advances in Protein Chemistry and Structural Biology series, covers chapters on various topics such as exploiting mechanisms behind senescence-like cell cycle arrest, viral infection through cell cycle regulation, analyzing drug-resistant mutations in CDK4 gene, identifying potential inhibitors through structure-based virtual screening approach, controlling cell proliferation by targeting CDK6, the role of the nucleolus in regulating cell cycle, chromatin regulators in DNA replication and genome stability maintenance, and the role of macrophages in cancer cell progression and targeted immunotherapies.

Format: Hardback
Length: 542 pages
Publication date: 01 May 2023
Publisher: Elsevier Science Publishing Co Inc

The control of cell cycle and cell proliferation is a fundamental aspect of biology, and it has been extensively studied in recent years. In this article, we will explore some of the latest advances in this field, including the exploitation of pivotal mechanisms behind the senescence-like cell cycle arrest, viral infection through cell cycle regulation, analyzing drug-resistant mutations in the CDK4 gene, and identifying potential inhibitors through structure-based virtual screening approaches.

Furthermore, we will discuss the role of the nucleolus in regulating cell cycle, chromatin regulators in DNA replication and genome stability maintenance during S-phase, the role of macrophages in cancer cell progression, and targeted immunotherapies.

Exploiting Pivotal Mechanisms Behind the Senescence-Like Cell Cycle Arrest:

Senescence is a cellular state characterized by a permanent arrest of the cell cycle, which prevents the cell from dividing and proliferating. Senescence-like cell cycle arrest has been observed in various contexts, including aging, cancer, and viral infection. Researchers have been exploring the mechanisms behind this arrest to develop new therapies for diseases such as cancer.

One of the key mechanisms behind senescence-like cell cycle arrest is the activation of the p53 tumor suppressor protein. p53 is a transcription factor that regulates the expression of genes involved in cell cycle control, DNA repair, and apoptosis. When p53 is activated, it induces the expression of genes that promote cell cycle arrest, such as p21 and p27.

Researchers have been studying the role of p53 in senescence-like cell cycle arrest in various contexts, including cancer. They have found that p53 is frequently mutated in cancer cells, which leads to the activation of the Wnt signaling pathway. The Wnt signaling pathway is a key driver of cancer cell proliferation, and it promotes the expression of genes that promote cell cycle progression.

To exploit the mechanisms behind senescence-like cell cycle arrest, researchers have been developing new therapies that target p53. These therapies include small molecules that inhibit the activity of p53, such as Nutlin-3a, and monoclonal antibodies that bind to p53 and induce apoptosis.

Viral Infection Through Cell Cycle Regulation:

Viral infection is a major cause of disease in humans and animals. Viruses hijack the cell cycle machinery to replicate their genetic material and infect new cells. Researchers have been studying the mechanisms by which viruses regulate the cell cycle to develop new antiviral therapies.

One of the key mechanisms by which viruses regulate the cell cycle is the activation of the cyclin-dependent kinase (CDK) family of enzymes. CDKs are enzymes that regulate the progression of the cell cycle by phosphorylating specific proteins, such as cyclin D and cyclin E. When CDKs are activated, they promote the transition from G1 to S phase, which is the stage of the cell cycle in which DNA replication occurs.

Researchers have been studying the role of CDKs in viral infection to develop new antiviral therapies. They have found that viruses hijack the cell cycle machinery by activating CDKs, which leads to the activation of DNA replication. They have also found that viruses use other mechanisms, such as the activation of the tumor suppressor protein p53, to regulate the cell cycle.

To develop new antiviral therapies, researchers have been developing small molecules that inhibit the activity of CDKs. These therapies include CDK inhibitors, such as palbociclib and ribociclib, which are currently being used in the treatment of breast cancer.

Analyzing Drug-Resistant Mutation in the CDK4 Gene and Identification of Potential Inhibitors through Structure-Based Virtual Screening Approach:

Drug resistance is a major challenge in the treatment of cancer. Cancer cells often develop mutations in genes that regulate the cell cycle, such as the CDK4 gene. These mutations lead to the activation of the cell cycle machinery, which promotes the proliferation of cancer cells.

Researchers have been studying the mechanisms by which cancer cells develop drug resistance to develop new therapies. One of the key mechanisms by which cancer cells develop drug resistance is the activation of the cell cycle machinery. Researchers have been developing new therapies that target the cell cycle machinery, such as CDK inhibitors.

To develop new therapies, researchers have been using structure-based virtual screening approaches. These approaches involve the use of computer simulations to predict the structure of potential inhibitors that bind to the CDK4 protein. Researchers can then use these simulations to screen potential inhibitors that have the potential to be developed into new therapies.

One of the most promising inhibitors that have been identified through structure-based virtual screening is palbociclib. Palbociclib is a CDK4 inhibitor that is currently being used in the treatment of breast cancer. Palbociclib has been shown to be effective in the treatment of breast cancer, and it has been shown to be effective in the treatment of other types of cancer, such as lung cancer and ovarian cancer.

Controlling Cell Proliferation by Targeting CDK6 Using Drug Repurposing Approach:

CDK6 is a member of the CDK family of enzymes that regulate the cell cycle. CDK6 is involved in the regulation of cell proliferation, and it is frequently overexpressed in cancer cells. Researchers have been studying the role of CDK6 in cancer cell proliferation to develop new therapies.

To develop new therapies, researchers have been using drug repurposing approaches. Drug repurposing involves the use of existing drugs to develop new therapies. Researchers have found that CDK6 inhibitors, such as palbociclib, can be used to control cell proliferation in cancer cells.

One of the most promising therapies that have been developed using drug repurposing is the combination of palbociclib and fulvestrant. Fulvestrant is a hormone therapy that is used to treat breast cancer. Palbociclib is a CDK4 inhibitor that can be used to control cell proliferation in breast cancer cells. The combination of palbociclib and fulvestrant has been shown to be effective in the treatment of breast cancer.

The Role of the Nucleolus in Regulating Cell Cycle:

The nucleolus is a structure in the nucleus of eukaryotic cells that is involved in the synthesis of ribosomes, which are responsible for the synthesis of proteins. The nucleolus is also involved in the regulation of the cell cycle. Researchers have been studying the role of the nucleolus in regulating cell cycle to develop new therapies for cancer.

One of the key mechanisms by which the nucleolus regulates cell cycle is the regulation of the expression of genes involved in cell cycle control. The nucleolus is involved in the regulation of the expression of genes such as cyclin D, cyclin E, and p21. When these genes are expressed, they promote the activation of the cell cycle machinery, which leads to the progression of the cell cycle.

Researchers have been studying the role of the nucleolus in regulating cell cycle to develop new therapies for cancer. They have found that drugs that inhibit the activity of the nucleolus can be used to control cell proliferation in cancer cells.

Chromatin Regulators in DNA Replication and Genome Stability Maintenance during S-Phase:

Chromatin is a complex structure that is responsible for the packaging of DNA in eukaryotic cells. Chromatin regulators are proteins that regulate the structure of chromatin, which in turn regulates the expression of genes. Chromatin regulators are also involved in the regulation of the cell cycle.

One of the key mechanisms by which chromatin regulators regulate the cell cycle is the regulation of DNA replication. Chromatin regulators such as histone deacetylases (HDACs) and chromatin remodeling complexes (CRCs) regulate the activity of DNA polymerases, which are responsible for the synthesis of DNA during DNA replication.

Researchers have been studying the role of chromatin regulators in DNA replication and genome stability maintenance during S-phase to develop new therapies for cancer. They have found that drugs that inhibit the activity of chromatin regulators can be used to control cell proliferation in cancer cells.

Role of Macrophages in Cancer Cell Progression and Targeted Immunotherapies:

Macrophages are immune cells that are involved in the immune response to infection and inflammation. Macrophages are also involved in the progression of cancer. Macrophages can promote the growth and survival of cancer cells by secreting growth factors and cytokines.

Researchers have been studying the role of macrophages in cancer cell progression to develop new therapies. They have found that drugs that inhibit the activity of macrophages can be used to control cell proliferation in cancer cells.

One of the most promising therapies that have been developed using targeted immunotherapies is the use of checkpoint inhibitors. Checkpoint inhibitors are drugs that block the activity of proteins that are involved in the immune response to cancer. Checkpoint inhibitors have been shown to be effective in the treatment of various types of cancer, including lung cancer and melanoma.

In conclusion, the control of cell cycle and cell proliferation is a fundamental aspect of biology, and it has been extensively studied in recent years. In this article, we have explored some of the latest advances in this field, including the exploitation of pivotal mechanisms behind the senescence-like cell cycle arrest, viral infection through cell cycle regulation, analyzing drug-resistant mutations in the CDK4 gene, and identifying potential inhibitors through structure-based virtual screening approaches. We have also discussed the role of the nucleolus in regulating cell cycle, chromatin regulators in DNA replication and genome stability maintenance during S-phase, the role of macrophages in cancer cell progression, and targeted immunotherapies. These advances have the potential to lead to new therapies for diseases such as cancer, and they have the potential to improve the quality of life for patients with cancer.

Weight: 938g
Dimension: 159 x 239 x 32 (mm)
ISBN-13: 9780443158223